Summary A study has been made of the way in which the number of events available for analysis in a clinical trial was dependent on the recruitment period, the maximum follow-up time on individual patients and the length of time between the start of the trial and its analysis. The events considered were deaths, local recurrences and late radiation effects on normal tissue in patients treated for cancer of the laryngo-pharynx by two different fractionation regimes. The The third time needing specification is that at which the results of the trial are to be analysed. While early interim analyses may be advisable to monitor the treatment effects, the use of any interim result to stop entry into the trial or to trigger early publication must take into account the effect of repeated analyses on apparent significance levels. This is a topic that has been discussed by many authors, e.g. Armitage et al. (1969), Haybittle (1971) We have recently studied the way in which events accumulated in a trial that began to be planned over 28 years ago. Our results show how, if we had, at the time of planning this trial, the requisite data concerning the time-course of occurrence of significant events, we could have saved ourselves and the trial participants considerable time and effort. Unfortunately there was a lack of suitable retrospective data on which to base such considerations and the trial design was very much influenced by the clinical concepts then current. Our experience may therefore be of value for others planning clinical trials of cancer treatment.
The power of a clinical trial to detect differences in the time to an event with a given level of statistical significance depends on the number of events observed where an event can be either death, recurrence, or some other 'failure' such as a late radiation effect on normal tissue. In trials of cancer treatment, this number depends on three time periods that should ideally be specified in the initial trial design.
The first is the time during which patient accrual into the trial takes place. This will be determined by the expected rate of entry of patients and the total number that are needed for the required power as given in tables such as those published by Freedman (1982) and Machin and Campbell (1987) . A statement of this number is now accepted as an essential part of the protocol of any clinical trial, but over-optimistic estimates of rate of entry and/or a lessening of enthusiasm of participating clinicians with time may result in the required number not being reached.
The second time period that will influence the number of events observed is the maximum length of follow-up of each individual patient. This is a topic seldom discussed in trial reports, perhaps because the general policy has been that follow-up should be for 'as long as possible' or to a conventional 5 or 10 years. However, detailed follow-up of patients in a multicentre trial involves considerable effort and expense. 'Flagging' patients in the UK with the Office of Population Censuses and Surveys (Peto et al., 1977 ) is a cheap method of ensuring that all deaths are known, but is of little use in following other end-points such as tumour recurrence, which may occur long before death or indeed not lead to death at all if a patient is cured by subsequent treatment. Up-to-date information about these other events can only be obtained from the patients' clinical records and requires contact between the trials centre and the treating clinician on a regular basis. Unnecessary extension of the follow-up period should, therefore, be avoided as far as the statistical considerations of the trial are concerned.
The third time needing specification is that at which the results of the trial are to be analysed. While early interim analyses may be advisable to monitor the treatment effects, the use of any interim result to stop entry into the trial or to trigger early publication must take into account the effect of repeated analyses on apparent significance levels. This is a topic that has been discussed by many authors, e.g. Armitage et al. (1969) , Haybittle (1971) and Pocock (1977 (Figure 1) , built up to a maximum in the sixth year, but decreased thereafter. It was decided to terminate entry after 10 years when a total of 713 patients who satisfied the protocol had been randomised. This decision was made partly because of the fall in the rate of entry and also because an estimate of the increase in power that would be achieved by continuing to recruit up to the projected 900 suggested that the costs involved outweighed the minimal benefit that would be achieved.
Another decision made at the start of the trial was that each patient should be followed up for a maximum of 10 years. This was because the incidence of late normal tissue effects was of particular interest and it was thought, at the time, that a substantial proportion of these effects might not be identifiable until between 5 and 10 years.
Several interim analyses were made and reported, the last of these being in the seventeenth year after the start of the trial (Wiernik et al., 1982) . The first three analyses were made during the recruitment period and were comparatively simple. They showed no significant difference between the two arms and gave no cause for considering stopping entry into the trial. A final analysis has now been made and its results are reported elsewhere (Wiernik et al., 1990 Figure 2c . The rise up to 10 years is mainly due to the increasing number of patients recruited into the trial, but after 10 years the curves become less steep and approach plateaus. This is particularly noticeable for recurrences and late effects.
The corresponding effects on the precision of the estimates of relative risk are shown in Figure 3 (see Appendix). It can be seen in Figure 3a that, although there was a large reduction in the 95% confidence limits as recruitment extended over the first 7 years (resulting in from 251 to 343 events depending on the end-point; Figure 2a ), the rate of reduction was very much slower thereafter. This is because of the inverse dependence of the confidence interval on the square root of the number of events, and will be a characteristic of all trials. Thus, the penalty incurred by stopping our trial short of its aimed total of 900 patients was small. With our final figure of 428 deaths, the 95% confidence limits on the log relative risk of death are ± 0.19. If we had achieved our original aim, these limits would have been reduced only a little further to+±0.17. Figure 3b shows that very little advantage was obtained by following up patients for as long as 10 years. For deaths, increasing the follow-up time from I to 5 years reduces the confidence limits from ± 0.34 to ± 0.22, but the further reduction achieved by extension to 10 years is only 0.03. For studying local tumour control and late effects, 2 years would have been sufficient, since the curves for these two end-points only fall by 0.01 between 2 and 10 years.
As far as analysis time was concerned (Figure 3c ), waiting unti'I 5 years after the end of recruitment (15 years after the start of the trial) achieved a reduction in the confidence limits on the log relative risk of death of 0.03, but waiting to the end of the 20-year period achieved a further reduction of only 0.01. For local recurrences and late effects, waiting the last 10 years reduced the confidence limits by only 0.01 so that a final analysis could well have been made soon after the end o)f the-recruitment nperiod. 
Discussion
The above results show that very little was gained by delaying the final analysis until all patients had been followed up for 10 years. Figure 4 , the curve for all local recurrences derived from our trial patients shows very clearly the small number of recurrences occurring in the second quinquennium of follow-up. About a quarter of the total observed deaths occurred after 5 years, but the effect of these in reducing the confidence limits was small (Figure 3b We can also see from this study that, although the trial (Makuch & Simon, 1978; Blackwelder, 1982; Rodary et al., 1989) have discussed the design and analysis of clinical trials where the aim is to demonstrate 'equivalence' between treatments. They point out that, for such trials, the usual test of the null hypothesis is inappropriate, since 'insufficient evidence to reject the null hypothesis does not imply evidence to accept it' (Blackwelder, 1982) . The correct procedure when comparing a new therapy which may be desirable on grounds other than those of tumour control or cure (three fractions per week in our case) with a standard therapy (five fractions per week) is to decide on the minimum difference in tumour control or cure which, if it existed in favour of the standard therapy, would be so clinically important that the new therapy could not be justified. This is then the hypothesis to be tested, and the P-value to quote is the probability of the observed result being consistent with the true difference being greater than or equal to the chosen minimum difference. If P is sufficiently small, we can reject the hypothesis and opt for the new therapy simply because of its socio-economic advantages.
As stated earlier, the initial intention in our trial was to enter enough patients to have a reasonable power (90%) of detecting a 10% difference in event-free rates at a 5% level of significance. We could therefore, as an example, choose 10% as being the minimum difference referred to above and test the hypothesis that the five fraction per week event-free rate minus the three fraction per week rate is greater than or equal to 10% at (say) 5 years. Since the event-free rates for both deaths and local recurrences at 5 years are about 55% (Figure 4) Large numbers of patients are required in trials of adequate power to test such differences. Using the formula given by Makuch and Simon (1978) , one may calculate that, with 713 patients and the critical difference set at 10%, the power of our trial was the not unreasonable value of 85%. But, if the hypothesis to be tested for rejection at the P = 0.05 level were that the difference is greater than or equal to 5%, then about 3,400 patients are required for the trial to have a power of 90% (Makuch & Simon, 1978) .
In summary, therefore, our experience emphasises the need, when planning a trial of cancer treatment, to give serious consideration first of all to the number of events required in order to obtain sufficient power to detect the percentage difference that will satisfy clinicians who will have to base any change in their method of treatment on the trial results. It is particularly important not to underestimate this number in a trial where the aim is to test therapeutic equivalence. Having decided on this number, then existing data on the pattern of deaths and recurrences in the disease should be used to determine the maximum follow-up time on each patient and the time for definitive analysis. Little will be gained by follow-up beyond the time when the event-free curves are beginning to flatten out, since the few extra events that will be recorded beyond this point contribute little to the precision of the estimates of treatment differences. Our trial has provided data on the pattern of deaths, local recurrences and late effects on normal tissue following the treatment of squamous cell carcinoma of the laryngopharynx, and these data can now be used as a guide in the conduct of future trials at this site. Had such data been available to us in 1962, when planning the trial, then it is clear that, instead of delaying our final definitive analysis until more than 20 years after the first patient entered the trial, we could have achieved an almost equivalent result 7-8 years earlier.
Appendix
Relative risk, log relative risk and difference in event-free rates The relative risk, R, is the ratio of the hazard rate in one group to that in the other group and is related to the log relative risk, A, by the equation:
The standard error of A is V-where V-l El' + E2' (Haybittle & Freedman, 1979 ), E, and E2 being the expected events on the null hypothesis in each arm of the trial. With approximately equal numbers of patients in each arm and A not very different from zero: El=E2=E, and V-'=2E-'=4d-' since d, the total number of events, equals El + E2 = 2E.
Thus V-1 = 2d-I and the 95% confidence interval on an estimate of A is from A -2 x 1.96d-I to A + 2 x 1.96d-1, i.e. the confidence limits are ± 3.92d-1. If A is small, then R! 1 + A, so that a log relative risk of 0.20 corresponds to a relative risk of 1.20 (more accurately 1.22 if no approximation is made). Thus confidence limits ± x on the estimate of log relative risk as shown in Figure 3 correspond to very similar confidence limits on the relative risk, when x is small. However, while the confidence interval on the former is set symmetrically about the estimate, the interval is not set symmetrically about the latter, and it is for this reason that the confidence limits for A rather than for R are plotted in Figure 3 .
A relative risk can be translated into a difference in eventfree rates at a given time by using the equation: P2 (pl)R where PI and P2 are the event-free rates at that time in groups 1 and 2 respectively and R is the relative risk, group 2 to group 1. The relationship does not depend on the form of the event-free curve but only on the proportional hazards 
